Longeveron Q2 EPS $(0.26), Sales $489.00K
Longeveron (NASDAQ:LGVN) reported quarterly losses of $(0.26) per share. The company reported $489.00 thousand in sales this quarter.
EXCLUSIVE: Longeveron Spikes As Lead Drug Produces Dose-Dependent Response In Aging Frailty Study; Primary Endpoint Not Met
Florida-based biopharma Longeveron Inc. (NASDAQ: LGVN), which is engaged in the development of cell therapies for chronic age-related and life-threatening conditions, announced Friday results for a mid-stage study of its lead candidate.
Earnings Scheduled For August 13, 2021
Companies Reporting Before The Bell
• Jaguar Health (NASDAQ:JAGX) is expected to report quarterly loss at $0.03 per share on revenue of $7.28 million.
Longeveron’s Novel Therapy Looks to Tackle COVID-19, Flu-Related ARDS
Photo by Anna Shvets from Pexels
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer’s Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start to the pharma reporting season.
Longeveron Announces First Patient Treated In Phase 2b Hypoplastic Left Hearth Syndrome Clinical Study
Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced
Longeveron Announces Two Abstracts Accepted For Presentation At The Gerontological Society Of America 2021 Annual Scientific Meeting
Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, today
Longeveron, Armed with Positive Results of Phase I Clinical Study of Lomecel-B Cell Therapy for Alzheimer’s Disease, Presenting at AAIC & Headed to Phase 2 Trials
Longeveron CEO Geoff Green presented at the Benzinga Global Small Cap Conference held on May 13-14, 2021. In addition to sharing the company’s corporate outlook, Green participated in a panel entitled “Investing in Longevity Science: The New Drugs & Therapies Designed to Prolong Your Lifespan.”